Jacob Kushner is an independent journalist who writes about migration, conflict and extremism, foreign aid, corruption and human rights abuses in East/Central Africa, the Caribbean, and Germany.

In 2013 he received an M.A. in political journalism from Columbia University, where he researched Chinese engagement in Africa and authored China’s Congo Plan, which was favourably reviewed in The New York Review of Books. In 2013 he conducted research for the ICIJ on their Offshore Leaks project, a precursor to the Panama Papers. In 2013 he conducted research for the ICIJ on their Offshore Leaks project, a precursor to the Panama Papers. He investigated terrorism against immigrants as a 2017-2018 Fulbright Fellow in Germany. In 2018 he was named a Finalist for the Livingston Award for Young Journalists for Excellence in International Reporting. Jacob is a 2019 Logan Nonfiction Fellow at the Carey Institute for Global Good.

His writing has been published by The New York Times Magazine, National Geographic, Harper’s, The Atlantic, VQR, Outside Magazine, the Atavist, the ICIJ, Pacific Standard, NewYorker.com, VICE magazine, The Guardian, Foreign Policy, The Nation, WIRED, Playboy, Newsweek, OZY, the Associated Press, the L.A. Times, Guernica, Moment Magazine, The Christian Science Monitor and elsewhere.

Basic information

Name
Jacob Kushner
Title
Independent journalist
Expertise
Politics, migration, foreign investment
Country
Kenya
City
Nairobi

Supported projects

On the trail of Chinese pharmaceuticals in Africa

  • Economy
  • Health
  • Industry

MOMBASA - Counterfeit and substandard drugs are believed to kill thousands of people annually. The trade of substandard or falsified medicines has grown to a $30 billion black market industry. Experts warn that the number of counterfeit or substandard goods entering Africa is on the rise. Kenya, with its international Port of Mombasa on the Indian Ocean, is one of the epicenters. What’s more, public health facilities in Kenya are often expensive, inefficient, and sometimes prone to stock-outs.

A Quinine injection produced by Chinese company